46 patents
Page 3 of 3
Utility
Immunomodulatory and Differentiating Function Selective Retinoid and Rexinoid Compounds In Combination with Immune Modulators for Cancer Immunotherapy
4 Mar 20
Disclosed herein are methods for treating cancer comprising administering CAR-modified immune cells and at least one Retinoic Acid Receptor and/or Retinoid X Receptor active agent.
Roshantha A. Chandraratna, Martin E. Sanders
Filed: 7 Nov 19
Utility
Treatment of Autoimmune Diseases with Combinations of RXR Agonists and Thyroid Hormones
18 Dec 19
The present specification provides methods of treating autoimmune diseases with a combination of a RXR agonist and a thyroid hormone.
Roshantha A. Chandraratna, Martin E. Sanders
Filed: 30 Oct 16
Utility
Treatment of Cancer with Combinations of RXR Agonists and Thyroid Hormones
4 Dec 19
The present specification provides methods of treating cancer with a combination of a RXR agonist and a thyroid hormone.
Roshantha A. Chandraratna, Martin E. Sanders
Filed: 30 Oct 16
Utility
Rar Selective Agonists In Combination with Immune Modulators for Cancer Immunotherapy
13 Nov 19
Disclosed herein are methods for treating cancer comprising administering CAR-modified immune cells and at least one Retinoic Acid Receptor agonist.
Roshantha A. Chandraratna, Martin E. Sanders
Filed: 22 Jul 19
Utility
Rar Selective Agonists In Combination with Immune Modulators for Cancer Immunotherapy
16 Oct 19
Disclosed herein are methods for treating cancer comprising administering CAR-modified immune cells and at least one Retinoic Acid Receptor agonist.
Roshantha A. Chandraratna, Martin E. Sanders
Filed: 25 Jun 19
Utility
Treatment of Muscular Disorders with Combinations of RXR Agonists and Thyroid Hormones
2 Oct 19
The present specification provides methods of treating a muscular disorder with a combination of a RXR agonist and a thyroid hormone.
Roshantha A. Chandraratna, Martin E. Sanders
Filed: 30 Oct 16